Md Saiful Islam Khan
- NKGen Biotech (NASDAQ:NKGN) has released additional phase 1 data on its autologous NK cell therapy SNK01 indicating the treatment led to cognitive and biomarker improvements.
- The therapy, given intravenously, was shown to cross the blood-brain barrier to improve Aβ42/40, Tau, and alpha-synuclein protein levels in cerebrospinal fluid.
- At week 11, one week after treatment ended, 50–70% of patients in the trial had either stable or improved CDR-SB, ADAS-Cog and/or MMSE scores.
- NKGen (NKGN) said no treatment-related adverse events were reported.
